These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15865122)

  • 1. Dupuytren's contracture; increased cellularity--proliferation, is there equality?
    Forsman M; Kallioinen L; Kallioinen M; Ryhänen J
    Scand J Surg; 2005; 94(1):71-5. PubMed ID: 15865122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease.
    Brickley-Parsons D; Glimcher MJ; Smith RJ; Albin R; Adams JP
    J Bone Joint Surg Am; 1981 Jun; 63(5):787-97. PubMed ID: 7240301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupuytren's contracture: morphological and biochemical changes in palmar aponeurosis.
    Hamamoto H; Ueba Y; Sudo Y; Sanada H; Yamamuro T; Takeda T
    Hand; 1982 Oct; 14(3):237-47. PubMed ID: 6130030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
    Bianchi E; Taurone S; Bardella L; Signore A; Pompili E; Sessa V; Chiappetta C; Fumagalli L; Di Gioia C; Pastore FS; Scarpa S; Artico M
    Clin Sci (Lond); 2015 Oct; 129(8):711-20. PubMed ID: 26201022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in Dupuytren's contracture.
    Pagnotta A; Specchia N; Greco F
    J Orthop Res; 2002 Jan; 20(1):163-8. PubMed ID: 11853085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix.
    Berndt A; Kosmehl H; Katenkamp D; Tauchmann V
    Pathobiology; 1994; 62(2):55-8. PubMed ID: 7524526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of histological patterns in clinically affected and unaffected palm regions in dupuytren's disease.
    Alfonso-Rodríguez CA; Garzón I; Garrido-Gómez J; Oliveira AC; Martín-Piedra MÁ; Scionti G; Carriel V; Hernández-Cortés P; Campos A; Alaminos M
    PLoS One; 2014; 9(11):e112457. PubMed ID: 25379672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupuytren's contracture: MR imaging findings and correlation between MR signal intensity and cellularity of lesions.
    Yacoe ME; Bergman AG; Ladd AL; Hellman BH
    AJR Am J Roentgenol; 1993 Apr; 160(4):813-7. PubMed ID: 8456670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine structural alterations of the palmar aponeurosis in Dupuytren's contracture. A combined scanning and transmission electronmicroscopic examination.
    Józsa L; Salamon A; Réffy A; Renner A; Demel S; Donhöffer A; Pintér T; Thöring J
    Zentralbl Allg Pathol; 1988; 134(1):15-25. PubMed ID: 3358315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the fibroblast in Dupuytren's contracture.
    Murrell GA
    Hand Clin; 1991 Nov; 7(4):669-80; discussion 681. PubMed ID: 1769989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The collagen changes of Dupuytren's contracture.
    Murrell GA; Francis MJ; Bromley L
    J Hand Surg Br; 1991 Aug; 16(3):263-6. PubMed ID: 1960490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The pathobiochemistry of Dupuytren's contracture].
    Bobiński R
    Chir Narzadow Ruchu Ortop Pol; 2009; 74(2):68-73. PubMed ID: 19514484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts.
    Shin SS; Liu C; Chang EY; Carlson CS; Di Cesare PE
    J Hand Surg Am; 2004 Sep; 29(5):809-14. PubMed ID: 15465229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An insight into Dupuytren's contracture.
    Murrell GA
    Ann R Coll Surg Engl; 1992 May; 74(3):156-60; discussion 161. PubMed ID: 1616255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation.
    Jemec B; Linge C; Grobbelaar AO; Smith PJ; Sanders R; McGrouther DA
    Chir Main; 2000 Feb; 19(1):15-22. PubMed ID: 10777424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence.
    Degreef I; De Smet L; Sciot R; Cassiman JJ; Tejpar S
    Clin Orthop Relat Res; 2009 Mar; 467(3):838-45. PubMed ID: 18958538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of contractile force by cultured Dupuytren's disease and normal palmar fibroblasts.
    Rayan GM; Tomasek JJ
    Tissue Cell; 1994 Oct; 26(5):747-56. PubMed ID: 9437248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of myofibroblasts in the dermis of patients with Dupuytren's contracture. A possible source for recurrence.
    McCann BG; Logan A; Belcher H; Warn A; Warn RM
    J Hand Surg Br; 1993 Oct; 18(5):656-61. PubMed ID: 8294839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.
    Verjee LS; Midwood K; Davidson D; Eastwood M; Nanchahal J
    J Cell Physiol; 2010 Sep; 224(3):681-90. PubMed ID: 20432463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.